|
2024
|
Invention
|
Non-natural 5'untranslated region and use thereof. Provided are mRNA comprising a non-natural 5'U... |
|
|
Invention
|
Non-natural 3' untranslated region and use thereof. Provided are: an mRNA comprising a non-natura... |
|
|
Invention
|
Nucleic acid molecule comprising modified polyadenylation sequence. Provided are: an mRNA molecul... |
|
|
Invention
|
Nucleic acid molecule comprising modified polyadenylation sequence and ox40l protein-coding seque... |
|
|
Invention
|
Pharmaceutical composition for preventing or treating cancer comprising nucleic acid structure en... |
|
|
Invention
|
Nucleic acid molecule comprising modified polyadenylation sequence and p53 protein coding sequenc... |
|
|
Invention
|
Novel skeletal derivative effective for her2 mutation, and pharmaceutical composition comprising ... |
|
|
Invention
|
Novel lyophilized formulation containing α-galactosidase a fusion protein. The present invention ... |
|
|
Invention
|
Solid dispersion of myeloid kinome inhibitors and pharmaceutical composition comprising the same.... |
|
|
Invention
|
Combination formulation comprising sacubitril-valsartan and sglt-2 inhibitor having improved stab... |
|
|
Invention
|
Combination therapy of interleukin-2 analog or conjugate thereof and immune checkpoint inhibitor ... |
|
|
Invention
|
Pharmaceutical composition for preventing or treating cancer including interleukin 2 analog or co... |
|
2023
|
Invention
|
Novel triple activator having activity on all of glp-1, gip, and glucagon receptors, and pharmace... |
|
|
Invention
|
Pharmaceutical composition for preventing or treating graft-versus-host disease containing glp-2 ... |
|
|
Invention
|
Antigenic peptide having multiple kras variant peptides linked thereto, nucleic acid encoding the... |
|
|
Invention
|
Formulation containing immunoactive interleukin 2 analog conjugate. The present invention relates... |
|
|
Invention
|
Novel crystalline form of a pyrimidine compound and pharmaceutical compositions comprising the sa... |
|
|
Invention
|
Novel pyrimidine derivative as bruton's tyrosine kinase inhibitor. The present disclosure relates... |
|
|
Invention
|
Novel glp-1 receptor antagonist, and pharmaceutical composition for preventing or treating congen... |
|
|
Invention
|
Novel tricyclic derivative compound and uses thereof. The present invention relates to a novel tr... |
|
|
Invention
|
Novel heterobicyclic compound for inhibiting yap-tead interaction and pharmaceutical composition ... |
|
|
Invention
|
Novel tricyclic heterocyclic carbaldehyde compound and pharmaceutical composition, containing sam... |
|
|
Invention
|
Lyophilized formulation comprising a fusion protein including a-galactosidase a.
The present inv... |
|
2022
|
Invention
|
Liver-targeted substance and use thereof.
A liver-targeted drug and therapeutic use thereof for ... |
|
|
Invention
|
Liver-targeted drug and use thereof.
A liver-targeted drug and therapeutic use thereof for disea... |
|
|
Invention
|
Coronavirus vaccine.
Provided are non-naturally occurring 5′-untranslated region and 3′-untransl... |
|
|
Invention
|
Method for preparing oral composite tablet containing proton pump inhibitor and antacid and oral ... |
|
|
Invention
|
Therapeutically effective combination of a flt3 inhibitor and a bcl-2 inhibitor for the treatment... |
|
|
Invention
|
Pikfyve kinase inhibitor.
The present disclosure relates to a thieno[3,2-d]pyrimidine derivative... |
|
|
Invention
|
Composition for orally administered formulation containing glp-1 analogue.
A composition, suitab... |
|
|
Invention
|
Therapeutic use of combination including triple agonist having activities to all of glucagon, glp... |
|
|
Invention
|
Oral complex tablet comprising sitagliptin, dapagliflozin, and metformin.
An oral dosage form in... |
|
|
Invention
|
Non-natural 5'-untranslated region and 3'-untranslated region and use thereof.
Provided is an is... |
|
|
Invention
|
Efpeglenatide to reduce risk of developing cardiovascular disease or renal dysfunction.
Provided... |
|
|
Invention
|
Pharmaceutical composition for preventing or treating chronic renal disease including glucagon de... |
|
|
Invention
|
Combination therapy with a raf inhibitor and a pd-1 axis inhibitor.
A combination therapy compri... |
|
|
Invention
|
Combination therapy with belvarafenib and cobimetinib or with belvarafenib, cobimetinib, and atez... |
|
|
Invention
|
Novel conjugate of immune-stimulating il-2 analog and preparation method thereof.
The present in... |
|
|
Invention
|
Belvarafenib for use in treatment of brain cancers.
Provided are methods for the use of belvaraf... |
|
|
Invention
|
Liquid formulation of protein and methods of preparing the same.
Provided are a liquid formulati... |
|
2021
|
Invention
|
Combination therapy of insulinotropic peptide and glp-2, for preventing or treating short bowel s... |
|
|
Invention
|
Novel triple agonist having activities on all of glucagon, glp-1, and gip receptors and use there... |
|
|
Invention
|
Use of therapeutic enzyme fusion protein in prevention and treatment of neuropathy caused by or a... |
|
|
Invention
|
Use of therapeutic enzyme fusion protein in prevention and treatment of renal diseases caused by ... |
|
|
Invention
|
Use of trigonal agonist having activities to all of glucagon, glp-1, and gip receptors in treatme... |
|
|
Invention
|
Pharmaceutical composition for preventing or treating lupus-related diseases comprising gip deriv... |
|
|
Invention
|
Pharmaceutical composition comprising glucagon/glp-1/gip triple agonist or long-acting conjugate ... |
|
|
Invention
|
Hypotensive pharmaceutical composition comprising triple activator having activity for all of glu... |
|
2020
|
Invention
|
Pharmaceutical composition comprising proton pump inhibitor and antacid.
One aspect provides a p... |
